Patients will receive cells due to the presence of refractory disease and/or high risk for disease relapse and/or residual detectable disease following conventional therapy at the time of the infusion. Ideally, patients should not receive other systemic antineoplastic agents for at least 6 weeks after infusion of TAA CTL (for purposes of evaluation), although such treatment may be added if deemed critical for patient care by the attending physician.